Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 2Completed 2Withdrawn 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Dermatologic 2Other hematologic neoplasm 1Breast 1

Conditions

Lymphoma, T-Cell, Cutaneous 5Mycosis Fungoides 3Multiple Myeloma 3Hodgkin Disease 3Lymphoma, T-Cell, Peripheral 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Lymphocytic, Chronic, B-Cell 2Breast Neoplasms 2Waldenstrom Macroglobulinemia 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Stomach Neoplasms 1Somatostatinoma 1Sezary Syndrome 1Neoplasms 1Melanoma 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Insulinoma 1Inflammatory Breast Neoplasms 1Glucagonoma 1Gastrinoma 1Esophageal Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Islet Cell 1

Interventions

Rituximab 30Cyclophosphamide 18fludarabine phosphate 14Filgrastim 12Mycophenolic Acid 11Antilymphocyte Serum 11Cyclosporine 10Whole-Body Irradiation 9Bortezomib 9Tacrolimus 8Radiotherapy 8Peripheral Blood Stem Cell Transplantation 8Methotrexate 6Lenalidomide 6Cord Blood Stem Cell Transplantation 6Busulfan 6Granulocyte Colony-Stimulating Factor 5venetoclax 4tanespimycin 4Polymerase Chain Reaction 4Methylprednisolone 4Melphalan 4Flow Cytometry 4Etoposide 4Bendamustine Hydrochloride 4ublituximab 3thymoglobulin 3pembrolizumab 3ibritumomab tiuxetan 3fludarabine 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Lymphoma, B-Cell, Marginal Zone × romidepsin × Clear all
NCT03432741 2025-05-26

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

Mayo Clinic

Phase 1 Terminated
17 enrolled
BreastDermatologicLymphoid

Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone

NCT01998035 2024-08-22

Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies

Columbia University

Phase 1/2 Terminated
58 enrolled 11 charts
DermatologicLymphoidOther hematologic neoplasm

Burkitt Lymphoma, Hodgkin Disease, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡